The reason it seems like you’re paying more for prescriptions might be because you’re paying more for prescriptions.
But not always for the reasons you might think. And some big employers in the Pittsburgh area are finding new ways of tamping down their spending for prescription benefits, even as drug list prices rise.
When consumers talk about rising drug prices, they usually mean how much they’re having to cough up at the pharmacy counter.
Although prescription prices have been outpacing the cost of living in recent years, less obvious are the tweaks that employers make to pharmacy benefit plans to shift a bigger share of prescription sticker prices to the consumer. New reports track the trend.
“Employer benefit designs increasingly expose patients to the list price of their prescriptions,” Adam J. Fein, CEO of Philadelphia-based Drug Channels Institute, wrote in a recent report. “Patients are finding their benefits to be increasingly mysterious, with more tiers, more coinsurance and greater use of deductibles” — all of which have people digger deeper into their pockets at the drugstore.
Employers are among the biggest payers for prescription drugs. Coinsurance — which requires consumers to pay a percentage of a drug’s price instead of a fixed copay amount — is one of the levers that employers are using to shift prescription costs to the employee.

But cost shifting may not be the only reason consumers are paying more.
Spending on outpatient prescriptions last year grew by 2.5%, which compares to a 1.4% increase in 2017, Mr. Fein wrote. Still, prescription spending trailed overall national health expenditures, which rose 4.6% in the same period.
“Some patients end up paying a much greater share of costs due to pharmacy benefit designs,” he wrote.
Copayments — the consumer’s contribution to the cost of a prescription — are a staple of drug benefit plans. The use of fixed copays decreased to 43% in 2016 from 48% in 2015 among 298 employers surveyed, according to a 2017 Pharmacy Benefit Management Institute report.
At that point, coinsurance took the lead in shifting cost strategies, according to the report, before losing popularity in 2018 and into 2019.
The average pharmacy coinsurance in 2016 was 38% — meaning consumers had to pay 38% of the drug’s list price — but average copays also rose between 2015 and 2016. Adding to the sting, employers could apply both levers to the same prescription purchase.
After several years of increases, the use of coinsurance as an employer cost shifting tool dipped between 2017 and 2018 — dropping 57% from 62% in a survey of 273 employers, said Sharon Glave Frazee, senior vice president of research and data innovation at the Pharmacy Benefit Management Institute.
Pushback from employees — or what Ms. Frazee calls “member noise” — may account for decline, which continued into 2019.
Still, employers continue to use copays, coinsurance and drug tiers in shifting prescription costs.
“More and more drugs are coming out and they’re not the cheap ones,” said Domenic Pasucci, funding consultant at Wexford-based health insurance broker My Benefit Advisor. “Employers are saying, ‘What can we do about this?’ It’s either shift the cost or raise the contributions.”
Nearly all big employers offer health care benefits that cover prescription drugs and the consumer’s share of drug costs is tied to tiers, which are created from the plan’s list of covered prescriptions.
Starting with generics on the lowest level, each tier requires a higher copay or coinsurance contribution. Specialty drugs, such as biologics, requiring the biggest contribution from plan members.
Pharmacy benefit managers often create the drug lists based on the size of the manufacturer’s rebate they receive, experts say, rather than the drug’s effectiveness.
In 2019, the four-tier design was the most common option for employer sponsored plans without high deductibles, Mr. Fein found, with fourth tier drugs having a coinsurance contribution of 29% compared to 18% for the generic tier.
The result: bigger out of pocket expenses for prescription drugs.
“How do you impact drug costs?” said Chris Robbins, CEO of Arxcel Consulting LLC, a Buffalo, N.Y.-based company that helps employers shrink drug spending. “The easiest answer is to shift costs to the patient.”
For two years, Mr. Robbins has collaborated with the Pittsburgh Business Group on Health in working to tamp down prescription costs for employers. Arxcel uses a pharmacy benefit manager who creates formulary drug lists based on how well the prescription works rather than the more common practice of adding a drug to the list based on the size of the rebate the PBM receives.
In the clinical- versus rebate-guided formulary, claims data are analyzed and doctors are advised about prescribing the drugs that are most effective.
PBGH members participating in the clinical model pharmacy plan have seen a return on investment of 3-to-1, Mr. Robbins said. And the good thing, he said, is “you never take the pen out of the doctor’s hand.”
business@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.